mafosfamide has been researched along with Kidney Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atzpodien, J; Duensing, S; Hadam, M; Kirchner, H; Körfer, A; Menzel, T; Poliwoda, H; Schomburg, A | 1 |
| Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH | 1 |
2 other study(ies) available for mafosfamide and Kidney Neoplasms
| Article | Year |
|---|---|
Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; Kidney Neoplasms; Lymphocyte Subsets; Male; Middle Aged | 1992 |
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; In Vitro Techniques; Interleukin-1; Kidney Neoplasms; Leukopenia; Lung; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neutropenia; Recombinant Proteins; Survival Analysis; Tumor Cells, Cultured | 1990 |